News

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

Matt Dickhut jokes he’s never won the Powerball, despite decades of trying his hand. But he did win the lottery. Instead of a big check, his winnings came in the form of a new liver.

“Physicians see all kinds of inequities in medical care and it’s heartbreaking. But we can take care of some of those things." —John Helzberg, MD

More than 100,000 people are on the wait list for a life-saving transplant—and more than 85% of those can be helped by a living donor.

Dr. Sanjaya Gupta, electrophysiologist at Saint Luke's Mid America Heart Institute, talks with KCTV about risk factors and new treatment available at Saint Luke's Atrial Fibrillation Clinic.

Through the Havertys' generosity, the Center has been able to create a national model of care called the Cardiometabolic Center Alliance.

When Shannon Clarke, a 48-year-old, retired police officer, received a heart from Saint Luke’s Mid America Heart Institute, he had no idea just how transformational it would be.